XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
Reinhardt, who helped GlaxoSmithKline get a gene therapy to market, joins XyloCor to advance genetic treatments for cardiovascular diseases.